Progenity, a biotech company innovating in the fields of women’s health, gastrointestinal health, and oral biotherapeutics had announced Adi Mohatny as the company’s new CEO. he also joins Progenity’s Board of Directors.
Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. The company’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.
“As we complete the execution of our strategic transformation, we are continuing to build biotechnology and biotherapeutics leadership capabilities to help ensure our success,” said Eric d’Esparbes, Chief Financial Officer and interim CEO. “To this end, we are delighted to welcome Adi Mohanty to Progenity as Chief Executive Officer. We believe he is the right person to lead Progenity into this next phase of growth as we advance the discovery, development, and delivery of therapeutics.”
“Progenity’s innovative platforms show substantial promise to change the way we diagnose and treat many complex diseases,” said Mr. Mohanty. “I am excited to be taking on this role, and I look forward to working alongside the Progenity board, management, and employees to accelerate the company’s transformation and realize the potential of its innovative technologies.”
Adi Mohanty is an experienced biotech business leader with a track record of several successful product development and approvals followed by rapid commercialization. Previously, he served as CEO of BioTime, where during his tenure, the company advanced its platform science to develop product candidates from the lab into mid- and late-stage clinical trials and unlocked value through strategic transactions, resulting in a better-capitalized company, poised to build substantial value for shareholders through renewed focus on clinical progress.
Adi formerly served as vice president at Transkaryotic Therapies, which was acquired by Shire PLC. Throughout a decade at Shire, he held several executive positions spanning global technical operations, product development, and commercial operations, culminating in the role of President, Regenerative Medicine. Earlier in his career, he held a variety of management positions in the bioscience division of Baxter Healthcare. Additionally, he has served as a board member for OncoCyte, a diagnostics company that he helped take public. Mr. Mohanty received his MBA at Saint Mary’s College, California. He also holds a Master of Science in Chemical Engineering from Clarkson University.
